Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease

Law, Cindy; Narula, Alisha; Lightner, Amy L.; McKenna, Nicholas P.; Colombel, Jean Fréd́eric; Narula, Neeraj

doi:10.1093/ecco-jcc/jjy022

Cited by 73 publications

(38 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering VDZ's gut selectivity, the safety profile has been shown to be favourable . One study using single‐centre data showed that VDZ exposure was not associated with post‐operative complications, including a recent meta‐analysis . However, since VDZ's mechanism of action blocks leucocyte migration into the intestinal lining, wound and anastomotic healing after IBD‐related surgery remains a potential concern .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk of post‐operative surgical site infections after vedolizumab vs anti‐tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease

Park

Sceats

Dehghan

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…20 One study using single-centre data showed that VDZ exposure was not associated with post-operative complications, 21 including a recent meta-analysis. 22 However, since VDZ's Data for this project were accessed using the Stanford Center for Population Health Sciences Data Core. The PHS Data Core is supported by a National…”

mentioning

confidence: 99%

Risk of post‐operative surgical site infections after vedolizumab vs anti‐tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease

Park

Sceats

Dehghan

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…They studied 146 patients who received vedolizumab 12 weeks before abdominal surgery and 289 patients who received anti-TNF therapy. However, two systematic reviews and meta-analysis [27,28] did not find increased risks of postoperative complications with the use of vedolizumab when compared to either preoperative anti-TNF therapy or no biological therapy. Studies regarding the use of ustekinumab comparing with anti-TNF therapy also demonstrated no increase in the risk of postoperative complications [29,30].…”

Section: Biological Therapy and Surgerymentioning

confidence: 98%

Biological Therapy for Inflammatory Bowel Diseases: Screening Prior to Initiating and How to Proceed When Surgery Is Necessary

Ayrizono¹,

Oliveira²,

Fagundes³

2020

Biological Therapy for Inflammatory Bowel Disease

View full text Add to dashboard Cite

Biological therapy has revolutionized the management of inflammatory bowel disease (IBD) in the last 30 years. However, these drugs have side effects and adverse events. Before starting this therapy, it is necessary to screen for specific infectious diseases and monitoring protocols. Screening for human immunodeficiency virus, hepatitis C, hepatitis B, and Mycobacterium tuberculosis infections must be included. In addition, vaccination should be checked and updated if necessary. Despite the advent of biological therapy, a significant number of patients with IBD will need surgery in their lifetime due to either clinical intractability or disease complications. Many of them will be on biological therapy, and there is a considerable controversy about adverse effects of biologics on surgical outcomes. In this chapter, we will approach the screening required to start this therapy and how to proceed when surgery is necessary in these patients.

show abstract

“…The impact of biologicals on postoperative complications is still controversial. Summary of previous reports is shown in Table . Large prospective studies are required to draw conclusions.…”

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Essential updates 2018/2019: Colorectal (benign)

Ogino

Mizushima

Matsuda

et al. 2019

Annals of Gastroent Surgery

View full text Add to dashboard Cite

This review outlines current topics on the surgical treatment of benign colorectal diseases, with a focus on inflammatory bowel disease (IBD) and diverticulitis. Treatment options for IBD and diverticulitis have evolved in the last few years as a result of medical advances in technology and new clinical trials. Therefore, treatment options and strategies need to be updated to provide optimal care for patients. The purpose of this review is to elucidate recent global trends and update the surgical treatment strategy for IBD and diverticulitis based on literature published in the past 2 years. Prevalence of IBD, including ulcerative colitis and Crohn's disease, has increased over the last few decades. During this period, many new medical therapies were introduced for the treatment of IBD, including biological therapy, immunomodulators, and leukocyte apheresis therapy. As a result, new surgical strategies for IBD are required. In order to improve surgical outcomes in IBD patients, the influence of preoperative treatment on postoperative complications needs to be considered. The incidence of diverticulitis is also increasing with lifestyle changes and increasing numbers of older people. For diverticulitis with perforation and generalized peritonitis, surgery is the gold standard. Elective surgery after conservative treatment of diverticulitis is also an option because of high recurrence rates. With an increase in diverticulitis, systematic strategies are essential for an appropriate approach to diverticulitis, taking into account various factors, including the patient's background.

show abstract

Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease

Cited by 73 publications

References 23 publications

Risk of post‐operative surgical site infections after vedolizumab vs anti‐tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease

Risk of post‐operative surgical site infections after vedolizumab vs anti‐tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease

Biological Therapy for Inflammatory Bowel Diseases: Screening Prior to Initiating and How to Proceed When Surgery Is Necessary

Essential updates 2018/2019: Colorectal (benign)

Contact Info

Product

Resources

About